Profound Medical Corp. (PROF)
NASDAQ: PROF · Real-Time Price · USD
7.25
-0.03 (-0.41%)
Dec 20, 2024, 4:00 PM EST - Market closed
Profound Medical Revenue
Profound Medical had revenue of $2.83M in the quarter ending September 30, 2024, with 63.89% growth. This brings the company's revenue in the last twelve months to $8.98M, up 39.35% year-over-year. In the year 2023, Profound Medical had annual revenue of $7.20M with 7.75% growth.
Revenue (ttm)
$8.98M
Revenue Growth
+39.35%
P/S Ratio
n/a
Revenue / Employee
$68,580
Employees
131
Market Cap
215.83M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 7.20M | 518.00K | 7.75% |
Dec 31, 2022 | 6.68M | -192.00K | -2.79% |
Dec 31, 2021 | 6.87M | -431.00K | -5.90% |
Dec 31, 2020 | 7.30M | 3.13M | 74.99% |
Dec 31, 2019 | 4.17M | 1.57M | 60.40% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
biote | 193.06M |
LifeMD | 193.06M |
SOPHiA GENETICS | 64.49M |
Zentalis Pharmaceuticals | 40.56M |
Inhibrx Biosciences | 1.57M |
Cardiff Oncology | 688.00K |
Inhibikase Therapeutics | 1.00 |
PROF News
- 11 days ago - Profound Medical Announces Closing of US$40.25 Million Underwritten Public Offering of Common Shares - GlobeNewsWire
- 15 days ago - Profound Medical Announces Pricing of US$35 Million Underwritten Public Offering of Common Shares - GlobeNewsWire
- 16 days ago - Profound Medical Announces Proposed Public Offering of Common Shares - GlobeNewsWire
- 19 days ago - Profound Medical and Siemens Healthineers to Offer a Complete Solution for MRI-guided Prostate Therapy - GlobeNewsWire
- 25 days ago - Profound Medical to Unveil Next TULSA-AI® Module, ‘UA Alignment Assistant' - GlobeNewsWire
- 5 weeks ago - Profound Medical Corporation (PROF) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Profound Medical Announces TULSA Reimbursement Raised to Urology APC Level 7 Under CMS Outpatient Prospective Payment System (OPPS) Final Rule for CY2025 - GlobeNewsWire
- 2 months ago - Profound Medical to Release Third Quarter 2024 Financial Results on November 7 – Conference Call to Follow - GlobeNewsWire